Dendreon's Provenge gets mixed grade in second Phase III

Dendreon announced that final three-year survival data from its second Phase III study of Provenge, the company's immunotherapy for prostate cancer, showed a survival benefit in men with advanced disease. Men taking the drug had a 20 percent better survival rate than those who received placebo, but these findings were not statistically significant. A secondary analysis adjusted for factors known to influence survival did, however, meet criteria for statistical significance. This is Dendreon's second phase III trial of the drug.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.